MorphoSys (MOR) News Today $18.96 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Novartis: launch of Morphosys drug by could be 2027 or laterNovember 21 at 3:12 AM | reuters.comIdiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).November 14, 2024 | theglobeandmail.comTango stock plunges 28% amid pipeline updates, Q3 earnings reportNovember 6, 2024 | msn.comMyrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma ReeveOctober 16, 2024 | finance.yahoo.comBiogen: Felzartamab Receives Breakthrough Therapy Designation - Quick FactsOctober 9, 2024 | markets.businessinsider.comNovartis Stock: Resilient Performance Amid Market VolatilityOctober 8, 2024 | finanznachrichten.deEnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategySeptember 26, 2024 | tmcnet.comNovartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerSeptember 17, 2024 | finanznachrichten.deMorphoSys AG: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | finanznachrichten.deEQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | markets.businessinsider.comMorphoSys (MOR) Set to Announce Earnings on ThursdayMorphoSys (NASDAQ:MOR) will be releasing earnings after the market closes on Thursday, August 29, Zacks reports. (Register for Conference Call at na)August 22, 2024 | marketbeat.comMORF Apr 2025 62.500 call(CONTR (MORF250417C00062500)August 18, 2024 | finance.yahoo.comIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaAugust 15, 2024 | stockhouse.comMorphoSys AG (MORD.XC)August 13, 2024 | uk.finance.yahoo.comMorphoSys AG (1MOR.MI)August 12, 2024 | sg.finance.yahoo.comRoyalty Pharma Reports Second Quarter 2024 ResultsAugust 8, 2024 | markets.businessinsider.comXencor Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | stockhouse.comEuropean Equities Traded in the US as American Depositary Receipts Plunge in Monday TradingAugust 5, 2024 | msn.comLeerink Partnrs Analysts Boost Earnings Estimates for MorphoSys AG (NASDAQ:MOR)MorphoSys AG (NASDAQ:MOR - Free Report) - Investment analysts at Leerink Partnrs raised their Q2 2024 earnings estimates for MorphoSys in a research note issued to investors on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0July 29, 2024 | marketbeat.comEVPassport Announces Opening of East Coast Headquarters in Boston and Key Executive Appointments Amidst Rapid GrowthJuly 25, 2024 | tmcnet.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MORJuly 16, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MORJuly 15, 2024 | prnewswire.comSusquehanna International Securities Ltd. Cuts Position in MorphoSys AG (NASDAQ:MOR)Susquehanna International Securities Ltd. reduced its position in shares of MorphoSys AG (NASDAQ:MOR - Free Report) by 74.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,041 shares of the company's stockJuly 14, 2024 | marketbeat.comMorphoSys: Novartis Deal Is All But DoneJuly 8, 2024 | seekingalpha.comHennion & Walsh Asset Management Inc. Has $2.12 Million Position in MorphoSys AG (NASDAQ:MOR)Hennion & Walsh Asset Management Inc. increased its position in MorphoSys AG (NASDAQ:MOR - Free Report) by 71.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,901 shares of the company's stock after buying an additional 48,710 shares duringJune 29, 2024 | marketbeat.comShort Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 65.0%MorphoSys AG (NASDAQ:MOR - Get Free Report) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 292,900 shares, a drop of 65.0% from the May 31st total of 837,600 shares. Based on an average daily trading volume, of 334,600 shares, the short-interest ratio is currently 0.9 days.June 27, 2024 | marketbeat.comMOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to ShareholdersJune 20, 2024 | businesswire.comMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority ShareholdersJune 20, 2024 | businesswire.comOpaleye Management Inc. Has $1.44 Million Stock Holdings in MorphoSys AG (NASDAQ:MOR)Opaleye Management Inc. cut its holdings in MorphoSys AG (NASDAQ:MOR - Free Report) by 88.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 145,000 shares of the company's stock after selling 1,064,380 shares during the quarter. Opaleye Management Inc. owneJune 15, 2024 | marketbeat.com4,234,685 Shares in MorphoSys AG (NASDAQ:MOR) Bought by Kynam Capital Management LPKynam Capital Management LP acquired a new stake in shares of MorphoSys AG (NASDAQ:MOR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,234,685 shares of the company's stock, valuedJune 10, 2024 | marketbeat.comMorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from BrokeragesShares of MorphoSys AG (NASDAQ:MOR - Get Free Report) have earned a consensus rating of "Hold" from the seven brokerages that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. TJune 9, 2024 | marketbeat.comMorphoSys AG (NASDAQ:MOR) Shares Purchased by TD Asset Management IncTD Asset Management Inc grew its position in shares of MorphoSys AG (NASDAQ:MOR - Free Report) by 153.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 361,138 shares of the company's stock after acquiring an additional 218,870 shares duJune 7, 2024 | marketbeat.comMonoclonal Antibody May Benefit Patients With Kidney Transplant RejectionMay 28, 2024 | msn.comNovartis releases Phase III data on its investigational oral therapy to treat chronic kidney diseaseMay 27, 2024 | msn.comMorphoSys (MOR) Scheduled to Post Earnings on MondayMorphoSys (NASDAQ:MOR) will be releasing earnings before the market opens on Monday, May 27, Yahoo Finance reports.May 26, 2024 | marketbeat.comNovartis Pharma AG: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | finanznachrichten.deNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | finance.yahoo.comNovartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash DealMay 16, 2024 | markets.businessinsider.comNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | globenewswire.comMorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from AnalystsShares of MorphoSys AG (NASDAQ:MOR - Get Free Report) have received a consensus recommendation of "Hold" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and three have assigned a buy rMay 15, 2024 | marketbeat.comMorphoSys (NASDAQ:MOR) Sets New 1-Year High at $18.38MorphoSys (NASDAQ:MOR) Sets New 52-Week High at $18.38May 14, 2024 | marketbeat.comShort Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 18.3%MorphoSys AG (NASDAQ:MOR - Get Free Report) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,250,000 shares, a drop of 18.3% from the April 15th total of 1,530,000 shares. Based on an average daily volume of 1,390,000 shares, the short-interest ratio is presently 0.9 days.May 13, 2024 | marketbeat.comMorphoSys (ETR:MOR) shareholders have earned a 228% return over the last yearMay 10, 2024 | finance.yahoo.comMorphoSys AG (MOR2.DU)May 6, 2024 | finance.yahoo.comHenry James International Management Inc. Takes $426,000 Position in MorphoSys AG (NASDAQ:MOR)Henry James International Management Inc. acquired a new position in shares of MorphoSys AG (NASDAQ:MOR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 43,000 sharMay 4, 2024 | marketbeat.comMorphoSys reports Q1 resultsApril 29, 2024 | msn.comEQS-News: MorphoSys AG Reports First Quarter 2024 Financial ResultsApril 29, 2024 | markets.businessinsider.comMorphoSys (NASDAQ:MOR) Shares Gap Down to $18.04MorphoSys (NASDAQ:MOR) Shares Gap Down to $18.04April 29, 2024 | marketbeat.comMorphosys says takeover by Novartis on course after report of drug safety concernApril 29, 2024 | uk.investing.comMorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, PelabresibApril 29, 2024 | benzinga.com Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. MOR Media Mentions By Week MOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOR News Sentiment▼0.400.46▲Average Medical News Sentiment MOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOR Articles This Week▼22▲MOR Articles Average Week Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News Today CTLT News Today SRPT News Today RVMD News Today QGEN News Today ITCI News Today ROIV News Today ASND News Today LEGN News Today ELAN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MOR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
